Unraveling the nexus: Tumor mutational burden, PD‐L1 expression, and oncogenic alterations in non–small cell lung cancer cytology specimens
Cancer Cytopathology · 2026-04 · 134 (4)
DOI: 10.1002/cncy.70090 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Cytopathology, online erschienen am 27.03.2026. Verfasst von Min Dai und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anatomical Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: B7-H1 Antigen, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Mutation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
PD‐L1 expression and tumor mutational burden (TMB) are biomarkers for immune checkpoint inhibitor (ICI) therapy in non–small cell lung cancer (NSCLC); however, patients harboring oncogenic alterations have limited benefit from ICIs. The impact of oncogenic alterations on TMB and PD‐L1 tumor proportion score in lung cytology specimens is poorly understood. Herein, the association between oncogenic alterations, TMB, and PD‐L1 in NSCLC cytology specimens is explored.
Methods
Next‐generation sequencing results from 312 NSCLC cytology specimens were retrospectively reviewed that interrogate 610 genes and select immuno‐oncology signatures. TMB and PD‐L1 immunohistochemical expression across oncogenic alterations were analyzed to explore associations.
Results
Of the 312 cases evaluated, 192 harbored NSCLC‐specific oncogenic alterations. Relative to EGFR ‐mutated tumors, TMB was significantly higher in KRAS ( p adj = 2.7 × 10 −4 ), ERBB2 ( p adj = .023), and BRAF ( p adj = .023) ‐mutated tumors but lower in ALK ‐rearranged tumors ( p adj = .005). Significantly higher PD‐L1 expression was seen in tumors with KRAS ( p adj = .002) and MET exon 14 ( p adj = 1.06 × 10 −4 ) when compared to EGFR ‐mutated tumors. Strong positive correlations between TMB and PD‐L1 were observed in ERBB2 ‐, KRAS ‐, and BRAF ‐mutated tumors when evaluated as continuous variables. TP53 mutations further enhanced immunogenicity when co‐occurring with KRAS , ERBB2 , or BRAF mutations but this effect was not observed in EGFR ‐mutated tumors.
Conclusions
These findings demonstrate distinct TMB and PD‐L1 profiles that may identify patients who will benefit from ICI therapy. Cytology specimens provide adequate material for biomarker testing, which underscores their value in guiding immunotherapy decisions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anatomical Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
ORCID-Profile: Min Dai, Shun Rao, Sinchita Roy-Chowdhuri
Zitieren
APA
Dai, M., San Lucas, F. A., Alvarez, H., Ballester, L., Chen, H., Patel, K. P., Rashid, A., Rao, S., Routbort, M. J., Sura, G., Sweeney, K., Toruner, G., Wei, P., Yang, R., Dang, H., Luthra, R., & Roy-Chowdhuri, S. (2026). Unraveling the nexus: Tumor mutational burden, PD‐L1 expression, and oncogenic alterations in non–small cell lung cancer cytology specimens. Cancer Cytopathology, 134(4). https://doi.org/10.1002/cncy.70090
Vancouver
Dai M, San Lucas FA, Alvarez H, Ballester L, Chen H, Patel KP, et al. Unraveling the nexus: Tumor mutational burden, PD‐L1 expression, and oncogenic alterations in non–small cell lung cancer cytology specimens. Cancer Cytopathology. 2026;134(4). doi:10.1002/cncy.70090
BibTeX
@article{Dai2026,
author = {Dai, Min and San Lucas, Francis Anthony and Alvarez, Hector and Ballester, Leomar and Chen, Hui and Patel, Keyur P and Rashid, Asif and Rao, Shun and Routbort, Mark J and Sura, Gloria and Sweeney, Keith and Toruner, Gokce and Wei, Peng and Yang, Richard and Dang, Hyvan and Luthra, Rajyalakshmi and Roy-Chowdhuri, Sinchita},
title = {Unraveling the nexus: Tumor mutational burden, PD‐L1 expression, and oncogenic alterations in non–small cell lung cancer cytology specimens},
journal = {Cancer Cytopathology},
year = {2026},
volume = {134},
number = {4},
doi = {10.1002/cncy.70090}
}
EUVIMED